MedPath

DARZALEX SC

DARZALEX SC

Approved
DIN Number

02502712

Drug Class

Human

Market Date

Aug 12, 2020

Company
HC

Janssen Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02502712
AIG Number0158231002
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D ,  Prescription
A
ATC Code
L01FC01 DARATUMUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationSubcutaneous
AHFS Classification10:00.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

DARATUMUMABActive
Strength: 1800 MG / 15 ML
Monograph: DARATUMUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.